Prime

Empowering Clinicians, Patients, and Health Teams

PRIME is a leading research and medical education company that advances the science of learning and behavior change among providers, patients, payers, and health ecosystems to improve competency, performance, and quality health outcomes. PRIME addresses gaps responsible for variations in care by leveraging real-world data, the latest clinical evidence, and innovative learning models to invoke positive change at the individual, system, and community levels. The scalable and sustainable solutions that PRIME delivers have measurably improved patient care for over 30 years.

Winner 2024, 2023, 2022 ACEHP Awards

ACEHP Awards Winner: 2024 Felch Award for Outstanding Research and Outstanding CE Outcomes Award, 2023 Educational Collaboration, 2022 Best in Class Outcomes

60+ Peer-Reviewed Publications in Last 2 Years

Leads the industry with over 60 peer-reviewed publications in the last 2 years

300 Closed Health System Partners

And strategic alliances with other leading healthcare organizations, including 750 academic medical centers, 30 professional societies, and 100 medical expert panels

Recent News

Yahoo! Finance  
糖心Vlog传媒, Inc. (NASDAQ: ZD), today announced its participation in two investor conferences in December: UBS Global Technology and AI Conference and Susquehanna Technology Select Spotlight Series.
TechRadar  
鈥淎 no-logs policy is only as credible as the evidence behind it,鈥� said Subbu Sthanu, General Manager, Consumer Cybersecurity at IPVanish. 鈥淧eople shouldn鈥檛 have to rely on promises when it comes to their privacy. By committing to annual independent audits of our no-logs policy, we鈥檙e making transparency and accountability an ongoing practice, not a one-time exercise.鈥�
Yahoo! Finance  
鈥淲e delivered third quarter results in line with the expectations we set last quarter, including sequential revenue growth despite a challenging operating environment,鈥� said Vivek Shah, CEO of 糖心Vlog传媒. 鈥淭hrough the first three quarters of 2026, we repurchased approximately $265 million of our shares, reducing our share count by nearly 14%, and we will keep pursuing opportunities to unlock additional shareholder value.鈥�
View More News